Results 11 to 20 of about 71 (52)

Infographic – Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design

, 2022
 Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design 
Neyssa Marina (12973781), Zev Wainberg (12973786), Eric Cheung (3555680), Peter Eisenberg (12973772), Daniel VT Catenacci (12973766), Mohamed Tejani (12973771), James Hnatyszyn (12973778), Janine Powers (12973783), Clarence Eng (12973775), Aaron J Scott (12973773), Figshare Future Science Group (6457551), Anteneh Tesfaye (12973768)   +11 more
core   +1 more source

FGFR families: biological functions and therapeutic interventions in tumors

MedComm, Volume 4, Issue 5, October 2023., 2023
FGFR amplification, mutations, fusions, or rearrangements can activate many pathways that lead to tumor development, and FGFR inhibitory drugs, especially TKIs, exert antitumor effects by blocking these pathways, but at the same time, secondary drug resistance inevitably arises in some patients, as overcoming drug resistance becomes a challenge that we
Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang   +5 more
wiley   +1 more source

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors

Cancer Science, Volume 114, Issue 2, Page 574-585, February 2023., 2023
This Phase I study aimed to determine the maximum tolerated dose and recommended dose of the FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors, and to examine the antitumor activity of the recommended dose. #10;Futibatinib had a generally predictable, monitorable, and clinically manageable safety profile; no dose‐limiting ...
Toshihiko Doi, Kohei Shitara, Takashi Kojima, Yasutoshi Kuboki, Nobuaki Matsubara, Hideaki Bando, Kiyotaka Yoh, Yoichi Naito, Hiroshi Hirai, Yukinori Kurokawa, Terufumi Kato, Chigusa Morizane   +11 more
wiley   +1 more source

Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer

Cancer Science, Volume 113, Issue 12, Page 4070-4081, December 2022., 2022
CD96+ cells infiltration represented an independent adverse prognosticator and could predict prognosis of adjuvant chemotherapy and therapeutic responsiveness to PD‐1 inhibitor. Immunosuppression by CD96 level was characterized by exhausted CD8+ T cells. Abstract CD96 was identified as a novel immune checkpoint. However, the role of CD96 in the gastric
Chang Xu, Hanji Fang, Yun Gu, Kuan Yu, Jieti Wang, Chao Lin, Heng Zhang, He Li, Hongyong He, Hao Liu, Ruochen Li   +10 more
wiley   +1 more source

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Journal of Oncology, Volume 2022, Issue 1, 2022., 2022
Aberrations in the fibroblast growth factor receptor2 (FGFR2) gene, including genetic alterations and chromosomal rearrangements, lead to the development and progression of cancer with poor prognosis. However, the mechanisms underlying the FGFR2 signaling pathway to facilitate the development of FGFR2‐targeted therapies have not been fully explored ...
Sujin Hyung, Boram Han, Jaeyun Jung, Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Dae Young Zang, Joon Oh Park, Young Suk Park, Kyoung-Mee Kim, Won Ki Kang, Jeeyun Lee, Guangzhen Wu   +12 more
wiley   +1 more source

Cellular and molecular mechanisms in fibrosis

Experimental Dermatology, Volume 30, Issue 1, Page 121-131, January 2021., 2021
Abstract The activation of fibroblasts is required for physiological tissue remodelling such as wound healing. However, when the regulatory mechanisms are disrupted and fibroblasts remain persistently activated, the progressive deposition of extracellular matrix proteins leads to tissue fibrosis, which results in dysfunction or even loss of function of
Clara Dees, Debomita Chakraborty, Jörg H. W. Distler   +2 more
wiley   +1 more source

memo - Magazine of European Medical Oncology / ASCO 2021 - Gastroesophageal tumor highlights

, 2021
The oncological community witnessed several practice-changing clinical reports in this years’ annual congress of the American Society of Clinical Oncology (ASCO). Many immunotherapeutic agents were shown to be beneficial for upper gastrointestinal tumors.
Ilhan-Mutlu, Aysegül
core   +1 more source

Carcinoma of unknown primary: Molecular tumor board‐based therapy

, 2022
CA: A Cancer Journal for Clinicians, Volume 72, Issue 6, Page 510-523, November/December 2022.
Aditya V. Shreenivas, Shumei Kato, Jingjing Hu, Catherine Skefos, Jason Sicklick, Razelle Kurzrock   +5 more
wiley   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Advances in therapeutic approaches to gastric cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis.
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He, Jia‐Fu Ji, Yuan‐Fang Li, Xiu‐Juan Qu, Yi Ba, Shu‐Qiang Yuan, Rui‐Hua Xu   +9 more
wiley   +1 more source